Olof TydÉn

Biography

Olof Tydén was appointed to the board of Oncopeptides in 2014. In addition to his directorship with Oncopeptides, Olof is a Partner at Eureda, an international pharmaceutical consulting firm. Olof has previously held positions as Medical Director at Leo Pharmaceuticals and Kabi-Vitrum (now Pfizer) and Programme Director at the Medical Products Agency in Sweden. Olaf was for six years Senior Regulatory Adviser at Hoffman-La Roche with responsibility for EU strategies, knowledge management and training. In 2000 he founded Eureda, a strategic regulatory consultancy. Olof has also served as an expert to the European Commission in Health Telematics and has been a member of the board of life sciences companies Bioxell SpA, Aprea AB, Cantargia AB and Ximmune AB. Olof holds a PhD from Uppsala University and an associate professorship in obstetrics and gynaecology at Uppsala University. Born: 1947 Holdings in Oncopeptides: 1,000 shares and 49 Share Options* Other current positions: Director of Eureda AB. Alternate Director of Uppsala Medical Information AB. Independent in relation to the Company, its senior management and major shareholders.

Research Interest

His research interests lie in Healthcare and Medical Sciences. He is the Editor-in-Chief Member of many peer reviewed journals and his area of expertise credits him with many publications in national and international journals. He is committed to highest standards of excellence and it proves through his authorship of many books.